Wall Street analyst estimates for Corbus Pharmaceuticals Holdings, Inc. (CRBP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid typ...
Valuation Ratios
| Price / Book | 1.40 |
| EV / EBITDA | -1.84 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.4M | $4.8M | $36.1M | $3.9M | $881705 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $15.4M | $26.0M | $48.6M | $89.6M | 0 | $1.6M | $1.5M | 0 | $600000 | 0 |
| Gross Profit | -$13.5M | -$23.6M | -$43.8M | -$53.5M | $3.9M | -$757527 | -$1.5M | 0 | -$600000 | 0 |
| Research & Development | $15.4M | $26.0M | $48.6M | $89.6M | $98.3M | $36.4M | $16.1M | $31.2M | $32.2M | $70.1M |
| Selling, General & Admin | $6.5M | $9.0M | $13.0M | $23.6M | $28.5M | $20.4M | $18.7M | $13.9M | $16.5M | $15.2M |
| Operating Expenses | $21.9M | $35.0M | $61.6M | $23.6M | $126.7M | $55.2M | $33.3M | $45.1M | $48.1M | $85.3M |
| Operating Income | -$20.0M | -$32.6M | -$56.7M | -$77.1M | -$122.8M | -$56.0M | -$34.8M | -$45.1M | -$48.7M | -$85.3M |
| EBITDA | -$19.9M | -$32.3M | -$56.3M | -$76.4M | -$121.1M | -$42.2M | -$38.7M | -$40.1M | -$37.7M | -$78.3M |
| Interest Expense | 0 | 0 | 0 | 0 | $1.0M | $1.8M | $2.1M | $2.9M | $1.9M | 0 |
| Pre-tax Income | -$20.0M | -$32.4M | -$55.7M | -$71.5M | -$111.3M | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Income Tax | $13617 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$20.0M | -$32.4M | -$55.7M | -$71.5M | -$111.3M | -$45.6M | -$55.8M | -$44.6M | -$40.2M | -$78.5M |
| EPS | $-14.58 | $-19.38 | $-29.30 | $-33.55 | $-42.72 | $-11.13 | $-10.15 | $-10.31 | $-3.68 | $-5.90 |
| EPS (Diluted) | $-14.58 | $-19.38 | $-29.30 | $-33.55 | $-42.72 | $-11.13 | $-10.15 | $-10.31 | $-3.68 | $-5.90 |
| Shares Outstanding (Diluted) | $1.4M | $1.7M | $1.9M | $2.1M | $2.6M | $4.1M | $4.2M | $4.3M | $10.9M | $13.3M |
Price
| Price | $7.26 |
| Market Cap | $135M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALEC · APLT · CRDF · ELTX · FBRX · IPHA · MIST
Explore sector: Healthcare · Biotechnology
More sections of CRBP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks